A Multi-center, Randomized, Double-blind, Placebo-controlled, Single Dose Efficacy and Safety Study of StaccatoTM Loxapine for Inhalation in Schizophrenic Patients With Agitation.
Phase of Trial: Phase II
Latest Information Update: 04 Jan 2018
At a glance
- Drugs Loxapine (Primary)
- Indications Agitation; Schizophrenia
- Focus Therapeutic Use
- Sponsors Alexza Pharmaceuticals
- 01 May 2008 Results will be presented at the 161st American Psychiatric Association annual meeting in May.
- 23 Jan 2007 Status change from in progress to completed.
- 23 Oct 2006 Status change
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History